EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived 21.11.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived Zentiva waives the condition of minimum acceptance Acceptance Period ends unchanged today, 21 November 2024 at 24:00 CET Around 60% of...
EQS-News: APONTIS PHARMA AG / Key word(s): 9 Month figures/Change in Forecast APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted 07.11.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted Revenue growth for Single Pill combinations in 9M 2024 to EUR 26.2 million (9M 2023:...
EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer/Statement Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer 30.10.2024 / 16:20 CET/CEST The issuer is solely responsible for the content of this announcement. Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer Joint reasoned statement by Management Board and Supervisory Board published Offer price of EUR 10.00 per share...
EQS-News: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer 16.10.2024 / 11:55 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer APONTIS PHARMA and Zentiva signed an investment agreement today Growth strategy of...
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Tender Offer APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer 16-Oct-2024 / 11:50 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Publication of inside information pursuant to Article 17 of the Regulation...
EQS-News: APONTIS PHARMA AG / Key word(s): Half Year Report/Half Year Results APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed 09.08.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed Revenue growth for Single Pill...
EQS-News: APONTIS PHARMA AG / Key word(s): Personnel APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company 27.06.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA AG appoints CFO Thomas Zimmermann to the Management Board with a view to the strategic development of the Company Monheim / Rhein, 27 June 2024 . APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5 ), a...
EQS-News: APONTIS PHARMA AG / Key word(s): Personnel APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management 04.06.2024 / 07:30 CET/CEST The issuer is solely responsible for the content of this announcement. APONTIS PHARMA continues to gear organization towards growth and internationalization – Renowned industry expert leads supply chain management Mila Brückel appointed as Head of Supply Chain Extensive...
